CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
We are pleased to inform you that the Canadian Cancer Trials Group (CCTG) is organizing our next Clinical Research Associate (CRA) Lunch and Learn training program, to be held on Wednesday, May 13th, 2026, at 12 pm ET on the topic: NCTN Clinical Trial Support Unit (CTSU) OPEN System and upcoming changes
Another successful CCTG Spring Meeting of Participants ended with ~900 network members, international friends and sponsors contributing to sessions and workshops to propose new trials and review current portfolio of activities. It was hectic but also inspirational.
A longer follow-up from the PR13/RADICALS-RT international study confirms that having radiotherapy only if the cancer returns, as opposed to having it soon after surgery, is a better approach for most people.
Findings from the CCTG PR13/RADICALS-HD study confirm that adding two years, compared to six months of hormone therapy delays prostate cancer spread in people who had surgery to remove the prostate followed by radiotherapy.
BRC2 (E1505): A phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected stage IB (>/= 4 cm) – III a non-small cell lung cancer (NSCLC) trial. NCT00324805: Results are available on www.clinicaltrials.gov
Congratulations to Sharon Turnell who was presented the CCTG Excellence in Clinical Trials Conduct Award at the CCTG Spring Meeting for her continued excellence in clinical trial operations and compliance at her home institution, Saint John Regional Hospital.
The Phase III Team Award for Intergroup-Led Trials was presented to the ME15 Team at Odette Cancer Centre (Sunnybrook Health Sciences Centre) at the CCTG Spring Meeting this weekend. The team members include, Dr. Frances Wright (QI), Roxana Marmolejo, Christina Siwak.
"We are absolutely thrilled to be the recipients of this CCTG Phase III Team Award. We have a fantastic team who work extremely hard to provide our patients with the option of participating in this potentially practice-changing trial, MelMart, the melanoma margins trial."
CCTG is honoured to recognize Dr. Hira Mian with the Ralph Meyer Phase III Program Young Investigator Award which is presented to a young investigator who worked on a Phase III trial and contributed significantly to the conduct the trial.
“I am thrilled to receive this young investigator award which is really on behalf of all my colleagues both at McMaster, CCTG and throughout Canada. Thank you team and looking forward to the many years of collaboration.”
